P1.01-001 Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA Trial

Authors :: Scott N. Gettinger
Maximilian Hochmair
M. Tiseo
Rudolf M. Huber
M-J. Ahn
Egbert F. Smit
Edward S. Kim
D.R. Camidge
David Kerstein
D. Kim
W. Reichmann
Karen L. Reckamp
Karin Holmskov Hansen
Howard West
Luis Paz-Ares
S.-B. Kim
Natasha B. Leighl
H. Groen
Corey J. Langer
Source :: Journal of Thoracic Oncology. 12:S1892
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: 0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
Target lesion
medicine.medical_specialty
Pathology
Brigatinib
business.industry
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
In patient
Association (psychology)
business

Full Text Access

Tools